icer glp 1 Raises Price Boundaries For GLP-1 Obesity Drugs In Latest Review GLP‑1 real‑world data for obesity:

Perhaps the biggest splash to the GLP-RA pool has come with the PIONEER trials for oral semaglutide

At 40 weeks, participants saw average A1C reductions of: 1.3% with the low dose 1.6% with the middle dose 1.5% with the high dose This compares to a 0.1% reduction in the placebo group

Clinical trial data from the SURMOUNT and SURPASS programs did not show dramatic differences in efficacy between abdominal, thigh, and upper arm injections for the majority of participants

Am J Physiol Endocrinol Metab 2010;298:E751-E760

Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why its common for patients to stop taking the medication

Patients with CKD and T2DM face a heightened risk of cognitive decline, driven by vascular dysfunction, insulin resistance, and chronic inflammation